How gut bacteria affect cancer treatment response
Role of Gut Microbiota in Modulating Immune Checkpoint Inhibitory Therapy for Cancer
['FUNDING_R01'] · UT SOUTHWESTERN MEDICAL CENTER · NIH-10738330
This study is looking at how the bacteria in your gut might help cancer treatments work better for melanoma patients, and it hopes to find ways to use good bacteria to boost your immune system during therapy.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UT SOUTHWESTERN MEDICAL CENTER (nih funded) |
| Locations | 1 site (DALLAS, UNITED STATES) |
| Trial ID | NIH-10738330 on ClinicalTrials.gov |
What this research studies
This research investigates the role of gut microbiota in enhancing the effectiveness of immune checkpoint inhibitor therapy for cancer patients. By analyzing the gut bacteria of melanoma patients, the study aims to identify specific microbial signatures that correlate with positive treatment outcomes. The researchers will explore the potential of precision probiotic therapy to improve immune responses against cancer by using beneficial bacteria identified in previous studies. This approach could lead to personalized treatment strategies that optimize cancer therapy based on individual microbiome profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are adult patients with melanoma or other cancers who are undergoing immune checkpoint inhibitor therapy.
Not a fit: Patients with cancers that do not respond to immune checkpoint inhibitors or those who are not eligible for such therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatment outcomes for patients through tailored probiotic therapies that enhance immune responses.
How similar studies have performed: Preliminary data suggests that similar approaches using gut microbiota have shown promise in enhancing cancer treatment responses, indicating potential for success in this research.
Where this research is happening
DALLAS, UNITED STATES
- UT SOUTHWESTERN MEDICAL CENTER — DALLAS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KOH, ANDREW — UT SOUTHWESTERN MEDICAL CENTER
- Study coordinator: KOH, ANDREW
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.